2022
Principles of Dose, Schedule, and Combination Therapy
Eder J, Hafez N. Principles of Dose, Schedule, and Combination Therapy. 2022, 1-13. DOI: 10.1002/9781119000822.hfcm055.pub3.Peer-Reviewed Original ResearchAcute myeloid leukemiaCombination chemotherapyMonoclonal antibodiesChemotherapeutic agentsHigh single-agent activityContemporary cancer therapyContinuous oral administrationSingle-agent activityBone marrow transplantationClinical toxicity profileCytotoxic chemotherapeutic agentsDose-response effectTyrosine kinase inhibitorsOutcome of therapyRapid plasma clearanceClinical trial designCombination of agentsDeoxyribonucleic acid damaging agentsNormal tissue recoveryPolymerase inhibitor rucaparibRole of doseMost chemotherapeutic agentsPrecise pathologic diagnosisTumor cell sensitivityHematopoietic growth factors
2016
Docetaxel in Advanced and Castration Resistant Prostate Cancer
Petrylak D, Hafez N. Docetaxel in Advanced and Castration Resistant Prostate Cancer. 2016, 77-92. DOI: 10.1007/978-3-319-31341-2_6.Peer-Reviewed Original ResearchResistant prostate cancerProstate cancerMetastatic castrate-resistant prostate cancerCastrate-resistant metastatic diseaseMetastatic castrate-resistant diseaseCastration-resistant prostate cancerCastrate-resistant prostate cancerResistant metastatic diseaseCastrate-resistant diseasePrimary chemotherapeutic agentStandard of careDocetaxel useTaxane cabazitaxelMetastatic diseaseDocetaxel efficacyRandomized trialsResistant diseaseLocal diseaseSuperior survivalDocetaxelChemotherapeutic agentsCancerDiseaseCorticosteroidsCabazitaxel